Government ❯ Regulation ❯ FDA

Drug Approval

Mifepristone Compounding Pharmacies Patient Safety Biologics License Application Safety Communications Clinical Trials Labeling Changes Agricultural Products Animal Health Solutions Sunscreen Ingredients Wegovy Pill Compounded Medications Exdensur Telehealth Public Health Breakthrough Therapy Designation Marketing Violations Environmental Impact Studies Advertising Standards Psychedelic Medications Healthcare Policies Peptide Regulation Sunscreen Regulation Psychedelic Drug OTC Monograph Mifepristone Approval Public Health Safety New Drug Application NDA

Atara Faces Investor Class Action Over FDA Rejections of EBVALLO

A May 22 deadline gives investors a window to seek lead-plaintiff status in the Central District of California case.

Class Action Filed Against Atara Biotherapeutics Over Alleged Misstatements on FDA Setbacks

FDA Warns ImmunityBio Over Anktiva Ads, Citing Misleading Cancer Claims

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

FDA Clears GSK’s Exdensur as First Twice-Yearly Add-On for Severe Eosinophilic Asthma

FDA Proposes Adding Bemotrizinol to U.S. Sunscreens, Invites Public Comment

FDA Grants Conditional Approval to Exzolt Cattle-CA1 for Screwworm and Cattle Fever Tick

FDA Investigates Fatal Liver Failures Linked to Sarepta’s Elevidys Therapy

Democratic-Led States Petition FDA to Remove Mifepristone Restrictions